Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Down 7.10%
As of Tuesday, November 17, Indaptus Therapeutics, Inc.’s INDP share price has dipped by 7.10%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Jenna Brashear
Jenna Brashear
Jenna Brashear
| Share Statistics | INDP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $480.7 | $212.8 | 38% |
|
| Shares Out (Mil) | 133.2 | 55.2 | 68% |
|
| Institutional Ownership | 0.9% | 93.3% | 2% |
|
| Float (Mil) | 45.3 | 40.8 | 44% |
|
| Beta | na | 1.03 | na |
|
| Avg Daily Volume (000s) | 235 | 559 | 47% |
|
| Price Change (52-week) |
35.5% | 40.3% | 81% |
|
| Growth | INDP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (42.0%) | (10.5%) | 9% |
|
| EPS (5yr) | 16.0% | 15.4% | 60 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.9% | (15.7%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | INDP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($14) | ($44) | 26% |
|
| EPS (TTM) | ($0.204) | ($1.400) | 32% |
|
| Operating Cash Flow (TTM) (Mil) | ($14) | ($34) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $456 | $142 | 34% |
|
| Valuation | INDP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 39.13 | 1.97 | 98% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | INDP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (70.9%) | (47.4%) | 8% |
|
| ROE | (180.7%) | (51.4%) | 4% |
|
| Liabilities to Assets | 66.9% | 29.6% | 62% |
|
| F-Score | 1 | 3 | 1% |
|
Indaptus Therapeutics, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors